| Syed Shabaz Azeem, MD | |
|
125 16th Ave E, Seattle, WA 98112-5211 | |
| (206) 326-3000 | |
| Not Available |
| Full Name | Syed Shabaz Azeem |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 24 Years |
| Location | 125 16th Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083870497 | NPI | - | NPPES |
| 196952901 | Medicaid | TX | |
| 03611490 | Medicaid | IL | |
| 206147137 | Other | IL | MEDICARE PTAN (INDIVIDUAL) |
| 206147 | Other | IL | MEDICARE PTAN (GROUP) |
| P01144158 | Other | IL | RAILROAD MEDICARE INDIVIDUAL PTAN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Medical Center / Cherry Hill | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.
Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.
The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
› Verified 5 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.
Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.
The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Syed Shabaz Azeem, MD 125 16th Ave E, Seattle, WA 98112-5211 Ph: (206) 326-3000 | Syed Shabaz Azeem, MD 125 16th Ave E, Seattle, WA 98112-5211 Ph: (206) 326-3000 |
News Archive
Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.
Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.
The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
› Verified 5 days ago
George A Ojemann, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-5637 | |
Mr. Trent Lane Tredway, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 737 Olive Way Apt 2502, Seattle, WA 98101 Phone: 206-623-1334 Fax: 206-623-1677 | |
Daniel A Lazar, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1560 N 115th St, 209, Seattle, WA 98133 Phone: 206-368-1701 Fax: 206-363-0019 | |
Mohammed Basamh, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 550 17th Ave Ste 500, Seattle, WA 98122 Phone: 206-320-2451 | |
Dr. Christoph Paul Hofstetter, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Campus Box 356470, Room Rr734, Seattle, WA 98195 Phone: 507-202-9523 | |
David Keisho Su, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 900 Lenora St, 501, Seattle, WA 98121 Phone: 559-260-0047 |